Results 61 to 70 of about 2,540 (169)

“Inclisiran: Early LDL-C target achievement in a real-life population”

Atherosclerosis Plus
Background and objectives: Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with atherosclerotic cardiovascular diseases. Inclisiran, a small interfering RNA, has been observed to effectively and sustainably reduce LDL-C in ...
Francesco Briani, Mauro Bagli, Gabriele Venturi, Francesco Bacchion, Antonio Mugnolo   +4 more
doaj   +1 more source

Comprehensive Review of Antiplatelet Therapy in Secondary Prevention of Myocardial Infarction: Mechanisms, Clinical Evidence, and Future Directions

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Atherosclerotic cardiovascular disease (ASCVD), particularly myocardial infarction (MI), is the leading cause of mortality and morbidity worldwide. The pathophysiology of MI involves atherosclerotic plaque rupture with thrombus formation, interrupting myocardial blood supply with subsequent myocardial necrosis.
May Thu Kyaw, Arkar Moe, Irfan Ahmad
wiley   +1 more source

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

International Journal of the Cardiovascular Academy
Hypercholesterolemia, a major contributor to atherosclerotic cardiovascular disease, remains inadequately controlled despite widespread statin use, particularly in patients with familial hypercholesterolemia or statin intolerance.
Agung Cendekia Putra Nusantara, Ariella Diandihati Rapsanjani, Ikhwan Handirosiyanto, Tara Mandiricha, Aisyah Silvia Gaffar   +4 more
doaj   +1 more source

Beyond lipids: Systemic effects of lipoprotein apheresis

Transfusion, Volume 66, Issue 3, Page 590-598, March 2026.
Menatalla Nadim, Yamac Akgun
wiley   +1 more source

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials

Endocrinology, Diabetes & Metabolism
Introduction Inclisiran, a small interfering RNA (siRNA), reduces the levels of low‐density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, there is limited pooled data
Jawad Basit, Mushood Ahmed, Priyansha Singh, Areeba Ahsan, Eeshal Zulfiqar, Javed Iqbal, Maurish Fatima, Prakash Upreti, Mohammad Hamza, M Chadi Alraies   +9 more
doaj   +1 more source

Inclisiran Usage in Very High-Risk Patients with Dyslipidemia Resistant to Statins and Ezetimibe Therapy

Український журнал серцево-судинної хірургії
Background. Complications of systemic atherosclerosis (myocardial infarction, ischemic stroke) are the main causes of mortality and disability in the modern world.
Є. Ю. Марушко, Г. Б. Маньковський, А. А. Левадська   +2 more
doaj   +1 more source

Treatment With Inclisiran During Peritoneal Dialysis

JACC: Case Reports
Inclisiran is a small interfering RNA that prevents PCSK9 (proprotein convertase subtilisin/kexin type 9) synthesis, lowering low-density lipoprotein cholesterol. In ORION trials, efficacy and safety outcomes of inclisiran were similar among different renal impairment degrees, but no data are available in peritoneal dialysis (PD).We present the case of
Sani E., Rinaldi E., Lupo M. G., Orlandi E., Molinaroli E., Giachetti G., Ferri N., Zoppini G.   +7 more
openaire   +3 more sources

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

Therapeutics and Clinical Risk Management, 2020
Constantine E Kosmas,1 Alba Muñoz Estrella,2 Andreas Skavdis,3 Edilberto Peña Genao,4 Ian Martinez,5 Eliscer Guzman1 1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA; 2Department of Medicine, Mount ...
Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E   +5 more
doaj  

Inclisiran til hyperkolesterolæmi

Ugeskrift for Læger
In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects.
Todorovac, Nerma, Hansen, Michael Skov, Elpert, Frank-Peter   +2 more
openaire   +1 more source

Retrospective Evaluation of LDL-C Levels Following First Treatment With Inclisiran as Part of Secondary Prevention ASCVD Risk Reduction in a Real-World Primary Care Setting

Journal of Primary Care & Community Health
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide. There is a direct relationship between increasing levels of LDL-C and increased risk of ASCVD.
Carl N. Deaney, Meredith P. Donaldson, Danielle M. Reesby, Victoria L. Scott, Victoria Ellis, Georgia E. Cole, Natalie M. C. Daly, Sophie C. McKechnie, Michelle Daff, Sarah L. Knudsen, Charles H. Hemingway-Deaney, Alena Nicholson, Laura Siauciuniene, Azeem Azeez, Agne Meskauskiene   +14 more
doaj   +1 more source